Filtered By:
Specialty: Drugs & Pharmacology
Infectious Disease: COVID-19

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 161 results found since Jan 2013.

Neurological associations of SARS-CoV-2 infection: A Systematic Review
CNS Neurol Disord Drug Targets. 2021 Feb 16. doi: 10.2174/1871527320666210216121211. Online ahead of print.ABSTRACTBACKGROUND: The current ongoing COVID-19 pandemic has compelled us to scrutinize major outbreaks in the past two decades, severe acute respiratory syndrome (SARS), in 2002, and Middle East respiratory syndrome (MERS), in 2012. We aimed to assess the associated neurological manifestations with SARS CoV-2 infection.METHODS: In this systematic review, a search was carried out by key-electronic databases, controlled vocabulary, and indexing of trials to evaluate the available pertinent studies which included both ...
Source: CNS and Neurological Disorders Drug Targets - February 17, 2021 Category: Drugs & Pharmacology Authors: Amaan Javed Source Type: research

Neurological associations of SARS-CoV-2 infection: A Systematic Review.
Abstract BACKGROUND: The current ongoing COVID-19 pandemic has compelled us to scrutinize major outbreaks in the past two decades, severe acute respiratory syndrome (SARS), in 2002, and Middle East respiratory syndrome (MERS), in 2012. We aimed to assess the associated neurological manifestations with SARS CoV-2 infection. METHODS: In this systematic review, a search was carried out by key-electronic databases, controlled vocabulary, and indexing of trials to evaluate the available pertinent studies which included both medical subject headings (MeSH) and advance electronic databases comprising of PubMed, Emba...
Source: CNS and Neurological Disorders Drug Targets - February 16, 2021 Category: Drugs & Pharmacology Authors: Javed A Tags: CNS Neurol Disord Drug Targets Source Type: research

Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach
The novel coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a wide range of manifestations. In this regard, growing evidence is focusing on COVID-19 neurological associations; however, there is a lack of established pathophysiological mechanisms and related treatments. Accordingly, a comprehensive review was conducted, using electronic databases, including PubMed, Scopus, Web of Science, and Cochrane, along with the author’s expertize in COVID-19 associated neuronal signaling pathways. Besides, potential phytochemicals have been provided against neurological signs...
Source: Frontiers in Pharmacology - January 20, 2021 Category: Drugs & Pharmacology Source Type: research

Nervous system complications of COVID-19 with a focus on stroke.
Authors: Zhou YL, Lu J, Cheng YB, Xin N Abstract As a severe and highly contagious infection, coronavirus disease (COVID-19) affects all aspects of society and has become a global public health problem. Because of the complexity of the pathology of COVID-19, it is difficult to treat. An increasing number of reports have indicated that COVID-19 may have neurological complications, including stroke. The nervous system complications of COVID-19 have gradually attracted research attention. In this review, we summarize the latest findings related to COVID 19, elaborate on the possible mechanism of COVID 19 related onset...
Source: European Review for Medical and Pharmacological Sciences - January 1, 2021 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Prognostic Genetic Markers for Thrombosis in COVID-19 Patients: A Focused Analysis on D-Dimer, Homocysteine and Thromboembolism
In this study, we aimed to uncover the genetic basis of the above conditions by examining genome-wide associations and tissue-specific gene expression to build a molecular network. Based on gene ontology, we annotated various SNPs with five ancestral terms: pulmonary embolism, venous thromboembolism, vascular diseases, cerebrovascular disorders, and stroke. The gene-gene interaction network revealed three clusters that each contained hallmark genes for D-dimer/fibrinogen levels, homocysteine levels, and arterial/venous thromboembolism with F2 and F5 acting as connecting nodes. We propose that genotyping COVID-19 patients f...
Source: Frontiers in Pharmacology - December 9, 2020 Category: Drugs & Pharmacology Source Type: research

Clinical characteristics and treatment outcome of COVID-19 patients with stroke in China: A multicenter retrospective study
Publication date: Available online 4 December 2020Source: PhytomedicineAuthor(s): Xin-yu Ji, Yan Ma, Nan-nan Shi, Ning Liang, Ren-bo Chen, Si-hong Liu, Shuai Shi, Gui-hui Wu, Ji-ke Li, Hong Chen, Jing-wei Wang, Hui Na, Ying-chun Zhou, Min-qing Li, Yu-dong Wang, Xiao-mei Hu, Yun-hong Hu, Zhang Liu, Hai-jun Xie, Lin-song Zhang
Source: Phytomedicine - December 5, 2020 Category: Drugs & Pharmacology Source Type: research

Neuronal and Cerebrovascular Complications in Coronavirus Disease 2019
Coronavirus disease 2019 (COVID-19) is a pandemic disease resulting from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, primarily in the respiratory tract. This pandemic disease has affected the entire world, and the pathobiology of this disease is not yet completely known. The Interactions of SARS-CoV-2 proteins with different cellular components in the host cell may be necessary for understanding the disease mechanism and identifying crucial pharmacological targets in COVID-19. Studies have suggested that the effect of SARS-CoV-2 on other organs, including the brain, maybe critical for understand...
Source: Frontiers in Pharmacology - November 20, 2020 Category: Drugs & Pharmacology Source Type: research

Impact of COVID-19 on the cerebrovascular system and the prevention of RBC lysis.
Authors: Akhter N, Ahmad S, Alzahrani FA, Dar SA, Wahid M, Haque S, Bhatia K, Sr Almalki S, Alharbi RA, Sindi AAA Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) uses Angiotensin- converting enzyme 2 (ACE2) receptors to infect host cells which may lead to coronavirus disease (COVID-19). Given the presence of ACE2 receptors in the brain and the critical role of the renin-angiotensin system (RAS) in brain functions, special attention to brain microcirculation and neuronal inflammation is warranted during COVID-19 treatment. Neurological complications reported among COVID-19 patients range from mi...
Source: European Review for Medical and Pharmacological Sciences - October 23, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.
CONCLUSION: Dipyridamole may substantially help improve the clinical outcomes of COVID-19 treatment. The pharmacokinetics profile of the drug is well established which makes it easier to design an appropriate therapeutic course. The drug is also generally safe, affordable, and available worldwide. Initial clinical trials have shown a substantial promise for dipyridamole in treating critically ill COVID-19 patients, yet larger randomized and controlled trials are needed to confirm this promise. PMID: 33001004 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - September 30, 2020 Category: Drugs & Pharmacology Authors: Aliter KF, Al-Horani RA Tags: Curr Pharm Des Source Type: research

Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
Abstract The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a lim...
Source: Acta Pharmacologica Sinica - September 22, 2020 Category: Drugs & Pharmacology Authors: Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD Tags: Acta Pharmacol Sin Source Type: research

Development of pulmonary embolism in a nonhospitalized patient with COVID-19 who did not receive venous thromboembolism prophylaxis.
CONCLUSION: This case suggests that nonhospitalized patients with COVID-19 may be at higher risk for VTE than patients with other medical illnesses and warrants further research into the risk of VTE in outpatients with COVID-19. PMID: 32780839 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - August 10, 2020 Category: Drugs & Pharmacology Authors: Uppuluri EM, Shapiro NL Tags: Am J Health Syst Pharm Source Type: research